News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
201,062 Results
Type
Article (9547)
Company Profile (27)
Press Release (191486)
Multimedia
Podcasts (6)
Webinars (2)
Section
Business (59085)
Career Advice (659)
Deals (11239)
Drug Delivery (25)
Drug Development (29114)
Employer Resources (40)
FDA (4995)
Job Trends (4596)
News (102155)
Policy (8126)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (512)
Accelerated approval (12)
Adcomms (6)
Allergies (69)
Alliances (7926)
ALS (92)
Alzheimer's disease (680)
Antibody-drug conjugate (ADC) (174)
Approvals (5321)
Artificial intelligence (263)
Autoimmune disease (93)
Automation (21)
Bankruptcy (78)
Best Places to Work (4096)
BIOSECURE Act (3)
Biosimilars (121)
Biotechnology (22)
Bladder cancer (130)
Brain cancer (26)
Breast cancer (445)
Cancer (2912)
Cardiovascular disease (227)
Career advice (541)
Career pathing (9)
CAR-T (126)
CDC (9)
Celiac Disease (1)
Cell therapy (334)
Cervical cancer (23)
Clinical research (27754)
Collaboration (831)
Company closure (1)
Compensation (590)
Complete response letters (13)
COVID-19 (878)
CRISPR (46)
C-suite (343)
Cystic fibrosis (60)
Data (4090)
Denatured (1)
Depression (66)
Diabetes (251)
Diagnostics (1993)
Digital health (20)
Diversity (1)
Diversity, equity & inclusion (10)
Drug discovery (115)
Drug pricing (48)
Drug shortages (11)
Duchenne muscular dystrophy (140)
Earnings (47630)
Editorial (15)
Employer branding (8)
Employer resources (35)
Events (30487)
Executive appointments (457)
FDA (6853)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (2)
Frontotemporal dementia (12)
Funding (725)
Gene editing (93)
Generative AI (12)
Gene therapy (273)
GLP-1 (468)
Government (1197)
Grass and pollen (4)
Guidances (362)
Healthcare (5324)
HIV (45)
Huntington's disease (17)
IgA nephropathy (46)
Immunology and inflammation (105)
Immuno-oncology (30)
Indications (66)
Infectious disease (1021)
Inflammatory bowel disease (88)
Inflation Reduction Act (5)
Influenza (53)
Intellectual property (83)
Interviews (127)
IPO (7184)
IRA (14)
Job creations (787)
Job search strategy (465)
JPM (20)
Kidney cancer (13)
Labor market (37)
Layoffs (157)
Leadership (6)
Legal (1485)
Liver cancer (40)
Longevity (2)
Lung cancer (424)
Lymphoma (276)
Machine learning (20)
Management (10)
Manufacturing (302)
MASH (81)
Medical device (4230)
Medtech (4255)
Mergers & acquisitions (4642)
Metabolic disorders (626)
Multiple sclerosis (112)
NASH (6)
Neurodegenerative disease (158)
Neuropsychiatric disorders (51)
Neuroscience (1341)
Neurotech (1)
NextGen: Class of 2026 (1485)
Non-profit (1068)
Now hiring (12)
Obesity (287)
Opinion (47)
Ovarian cancer (87)
Pain (85)
Pancreatic cancer (124)
Parkinson's disease (150)
Partnered (6)
Patents (184)
Patient recruitment (234)
Peanut (24)
People (7338)
Pharmaceutical (7)
Pharmacy benefit managers (13)
Phase 1 (7272)
Phase 2 (11908)
Phase 3 (10813)
Pipeline (3726)
Policy (59)
Postmarket research (1068)
Preclinical (2287)
Press Release (27)
Prostate cancer (146)
Psychedelics (10)
Radiopharmaceuticals (94)
Rare diseases (423)
Real estate (915)
Recruiting (16)
Regulatory (7454)
Reports (17)
Research institute (518)
Resumes & cover letters (112)
Rett syndrome (24)
RNA editing (4)
RSV (48)
Schizophrenia (84)
Series A (104)
Series B (101)
Service/supplier (3)
Sickle cell disease (63)
Special edition (9)
Spinal muscular atrophy (92)
Sponsored (10)
Startups (640)
State (1)
Stomach cancer (8)
Supply chain (55)
Tariffs (19)
The Weekly (5)
Vaccines (420)
Venture capital (36)
Weight loss (187)
Women's health (41)
Worklife (9)
Date
Today (84)
Last 7 days (353)
Last 30 days (1193)
Last 365 days (16519)
2026 (2143)
2025 (16920)
2024 (14760)
2023 (14315)
2022 (16776)
2021 (16234)
2020 (15541)
2019 (12785)
2018 (9784)
2017 (9333)
2016 (7966)
2015 (9632)
2014 (7086)
2013 (5215)
2012 (5911)
2011 (6161)
2010 (5233)
Location
Africa (220)
Alabama (18)
Alaska (2)
Arizona (83)
Arkansas (6)
Asia (12809)
Australia (2217)
California (6261)
Canada (1493)
China (571)
Colorado (246)
Connecticut (319)
Delaware (253)
Europe (31324)
Florida (689)
Georgia (160)
Hawaii (3)
Idaho (13)
Illinois (466)
India (33)
Indiana (251)
Iowa (11)
Japan (312)
Kansas (61)
Kentucky (17)
Louisiana (12)
Maine (42)
Maryland (570)
Massachusetts (4476)
Michigan (115)
Minnesota (291)
Mississippi (3)
Missouri (67)
Montana (11)
Nebraska (6)
Nevada (72)
New Hampshire (35)
New Jersey (1750)
New Mexico (6)
New York (1515)
North Carolina (725)
North Dakota (3)
Northern California (3138)
Ohio (146)
Oklahoma (5)
Oregon (10)
Pennsylvania (1084)
Puerto Rico (5)
Rhode Island (18)
South America (327)
South Carolina (17)
Southern California (2386)
Tennessee (75)
Texas (891)
United States (21036)
Utah (135)
Virginia (142)
Washington D.C. (34)
Washington State (504)
West Virginia (2)
Wisconsin (96)
201,062 Results for "6".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Pfizer Is Not a Done Dealmaker After Metsera Buy, With $6B More To Spend
With $6 billion left in firepower, Pfizer is planning transactions in the hundreds of millions to the low-billions range, particularly in internal medicine and immunology and inflammation, Guggenheim reported.
December 10, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
AtaiBeckley To Host Virtual Investor Day on March 6, 2026
February 20, 2026
·
1 min read
Press Releases
Attivare Therapeutics Awarded $6.6 Million Grant to Advance Durable Malaria Vaccine
December 15, 2025
·
2 min read
Press Releases
Spyre Therapeutics Announces Grants of Inducement Awards - February 6, 2026
February 9, 2026
·
1 min read
Press Releases
Lyric Bio, Inc. Closes $6.6 Million Seed Financing To Revolutionize Donor-Derived Therapeutics
December 3, 2025
·
3 min read
FDA
6 FDA Decisions To Watch in Q1 2026
After greenlighting 56 novel therapeutics in 2025, four notable applications continue to await the agency’s action after being delayed from the fourth quarter last year.
January 12, 2026
·
8 min read
·
Tristan Manalac
Press Releases
Mainz Biomed Announces 6.0 USD Million Private Placement and Strategic Update
February 17, 2026
·
4 min read
Press Releases
The Prostate Cancer Foundation Invests $6.3 Million in Next Generation of Prostate Cancer Researchers
February 17, 2026
·
2 min read
Cell Therapy
6 Companies Hanging On in Cell Therapy
As big pharmas including Takeda and Novo Nordisk flee the cell therapy space and smaller biotechs shutter their operations, these players are sticking around to take the modality as far as it can go.
December 1, 2025
·
9 min read
·
Tristan Manalac
Pipeline
Novartis Cuts 6 Early Cancer Candidates, Adds 2 to Refine Oncology Strategy
Despite the Phase 1 cull, CEO Vas Narasimhan on Wednesday maintained that Novartis continues to invest in its early-stage pipeline, looking for deals in the “sub-$2-billion range.”
February 5, 2026
·
2 min read
·
Tristan Manalac
1 of 20,107
Next
